|
|
| General |
| Study Status |
Completed |
Application Number /
Requirement Number |
P030053 / PAS004 |
| Date Original Protocol Accepted |
11/17/2006
|
| Date Current Protocol Accepted |
11/17/2006
|
| Study Name |
Adjunct Study
|
| Device Name |
MEMORYGEL SILICONE GEL -FILLED BREAST IMPLANTS
|
| General Study Protocol Parameters |
| Study Design |
Prospective Cohort Study
|
| Data Source |
New Data Collection
|
| Comparison Group |
No Control
|
| Analysis Type |
Analytical
|
| Study Population |
Adolescent: 13-18 yrs,
Transit. Adolescent B (as adults) : 18-21 yrs,
Adult: >21
|
| Detailed Study Protocol Parameters |
| Study Objectives |
The Adjunct study is a 5-year study, in which patients will be followed at 1, 3, and 5 years postoperatively to assess satisfaction and occurrence of local complications.
|
| Study Population |
The study population is as per device indication. This device is indicated for breast augmentation for women at least 22 years old and for breast reconstruction for women of any age. Breast Augmentation includes primary breast augmentation to increase the breast size, as well as revision surgery to correct or improve the results of a primary breast augmentation surgery. Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the results of a primary breast reconstruction surgery.
|
| Sample Size |
number of study sites: 2,958; 12,811 reconstruction patients were implanted with 23,090 implants
|
| Key Study Endpoints |
Safety endpoints include clinical complications such as infection, seroma, implant rupture and capsular contracture at 1 ,3, 5 years of follow-up and rheumatologic/immunologic symptoms and connective tissue disorders at 3, 5 years of follow-up
|
| Follow-up Visits and Length of Follow-up |
3 follow-up visits during 5 years of study (1, 3, 5 years post-implantation)
|
| Interim or Final Data Summary |
| Interim Results |
A total of 136,609 patients implanted with MemoryGel breast implants for reconstruction and revision-reconstruction were enrolled in the Adjunct study. The overall patient follow-up rates at 1, 3 and 5 years were 35.7%, 24.0% and 16.0% respectively.
|
| Actual Number of Patients Enrolled |
147,585
|
| Actual Number of Sites Enrolled |
4,684
|
| Patient Follow-up Rate |
44.0% at 1 year, 24.7% at 3 years, 13.8% at 5 years
|
| Final Safety Findings |
The 3 most commonly reported complications using the Kaplan-Meier cumulative incidence estimates at
5 years were: asymmetry (18.6%), wrinkling (9.9%), and Capsular Contracture, Baker III/IV (8.3%) in the Reconstruction Cohort; asymmetry (23.7%), wrinkling (14.3%), and Capsular Contracture, Baker III/IV (11.7%) in the Revision-Reconstruction Cohort; wrinkling (12.3%), asymmetry (11.4%), and Capsular Contracture, Baker III/IV (9.2%) in the Revision- Augmentation Cohort.
The most common reasons by cohort for removal were: capsular contracture (36.4%), infection
(13.2%), and patient request for size and implant change (10.5%) in the Reconstruction Cohort;
capsular contracture (37.4%), leakage/rupture/ deflation (12.2%), and infection (11.5%) in the Revision-Reconstruction Cohort; capsular contracture (36.1%), leakage/rupture/ deflation (16.1%), and patient request for size and implant change (10.3%) in the Revision-Augmentation Cohort.
The Kaplan-Meier cumulative rupture rates at 5 years were: 1.8% in the Reconstruction Cohort; 3.6%
in the Revision-Reconstruction Cohort; 3.5% in the Revision-Augmentation Cohort.
Bilateral implantation, white, infra-mammary surgical approach and sub-glandular surgical approach showed a higher risk of rupture, and reconstruction, smooth surface implant, high profile implant, high education and sub-muscular surgical placement showed a lower risk of rupture.
Rheumatoid arthritis was the most common patient-reported rheumatic disease at 0.6%. Fibromyalgia and Raynaud's phenomenon were the most commonly reported rheumatic syndromes at 0.8% and 0.5% respectively.
|
| Final Effect Findings |
N/A
|
| Study Strengths & Weaknesses |
A large number of patients were enrolled in the adjunct study. However, the study was originally
designed to address the public health needs of reconstruction and revision patients before device approval and to gather safety data regarding short-term post-implant complications under a limited clinical protocol without follow-up goals. The overall patient follow-up rates at 1, 3 and 5 years in this final report were only 44.0%, 24.7% and 13.8% respectively. The poor patient compliance significantly limited meaningful interpretation of the available safety results.
|
| Recommendations for Labeling Changes |
No
|
